BACKGROUND: Different treatment policies can influence biliary atresia outcomes, but the pathophysiology of expanding fibrosis occurring even after successful portoenterostomy remains unclear.
Biliary atresia (BA) is an idiopathic cholangiopathy of infancy characterized by fibro-inflammatory obstruction of extrahepatic bile ducts, leading to cholestasis and eventually cirrhosis. 1 Adjacent to biliary fibrosis, chronic cholestasis promotes proliferation of bile ductules, called ductal reaction. 2 The first-line treatment for BA is portoenterostomy (PE), which typically restores adequate bile flow in approximately half of patients. [3] [4] [5] [6] [7] It remains unclear why destruction of intrahepatic bile ducts, which promotes progressive liver damage, continues after resolution of jaundice. 8 Additional understanding of the pathophysiology driving liver injury is essential for novel approaches designed to extend native liver survival. Biliary atresia is the most common indication for pediatric liver Disclosure Information: Nothing to disclose. Support: This study was supported by the Sigrid Jusélius Foundation, the Finnish Pediatric Research Foundation, and the Helsinki University Central Hospital Grant #TYH2015219. Drs Hukkinen and Kerola contributed equally to this work. transplantation (LT), which is required in 70% to 80% of patients within 20 years of PE. 9, 10 After successful PE, plasma bilirubin levels normalize, which postpones the need for LT and improves patient survival. 11, 12 Portoenterostomy success rates are influenced by several patient-dependent factors, such as age at operation, 3, 6, 13 anatomy of the biliary tract remnant, 13, 14 coexistent congenital malformations, 3, 6, 7 and liver histologic features at PE, including degrees of fibrosis and ductal reaction. [15] [16] [17] [18] Postoperative steroids can improve clearance of jaundice (COJ) rates, although their effect on native liver survival remains unestablished. 19, 20 In addition, hospitals with low caseloads can have inferior outcomes compared with more experienced centers, 4, 7, 21 which has led to centralization of BA treatment, at least in the UK and Finland. 4, 21 After national centralization of BA management in Finland to Helsinki University Children's Hospital, results of the initial short-term follow-up demonstrated significantly improved COJ and transplant-free survival rates. 4 To improve BA management and to better understand the pathophysiology behind progressive liver damage, protocol native liver biopsies at PE and during follow-up were started after centralization. 22 Here, we evaluate the effect of centralization on BA outcomes after more than a decade of follow-up and compare the outcomes with those obtained in Helsinki before centralization. In addition, we address predictors of COJ, native liver survival, and overall survival, and analyze how liver histopathology at PE and during follow-up relates to these outcomes.
METHODS Ethics
This study was approved by the Ethical Committee of Helsinki University Hospital and the Finnish National Authority of Medicolegal Affairs and Health. A consent from participants or their caregivers was obtained before any procedures.
Patients
In 2005, the Ministry of Health centralized BA management in Finland from 5 university hospitals to Helsinki University Children's Hospital, which is a tertiary referral center for pediatric liver diseases with a nationwide LT program since 1987. All BA patients managed in Helsinki during 1987 to 2016 with at least a 4-month follow-up after primary operation were included. Biliary atresia diagnosis was confirmed by operative findings; perioperative cholangiography, when possible; and histopathologic assessment of the biliary remnant. Medical records were reviewed for gestational age and weight, associated congenital malformations, anatomic type of BA, 23 details of operative management, COJ rate, LT listing and performance, and possible death. Biliary atresia splenic malformation syndrome (BASM) was defined as presence of poly-or asplenia. 24 Clearance of jaundice was defined as serum total bilirubin <20 mmol/L at any time point postoperatively. Bilirubin levels were recorded at 3 and 6 months after PE, as well as at last follow-up.
Management of biliary atresia
In contrast to the variable follow-up and medical management practices performed before centralization, management and follow-up of BA were standardized in 2005, and a single team led by 1 surgeon operated on patients thereafter. Ursodeoxycholic acid (30 mg/kg/d), thrimetoprim-sulfadiazine (4 þ 12.5 mg/kg/d), and dexamethasone with decreasing doses (0.6 to 0.2 mg/kg/d, days 5 to 28) were routinely administered postoperatively. [25] [26] [27] Enteral energy provision was aimed at 150 kcal/kg/d with use of carbohydrate and medium chain fatty acid energy supplements. 28 Fat-soluble vitamin supplements were continued after discharge together with ursodeoxycholic acid and thrimetoprim-sulfadiazine. 4, 28 Follow-ups were arranged at 3-month intervals in local hospitals and at least once a year in Helsinki.
Liver histology Liver biopsies at PE and at last follow-up were analyzed and the changes occurring in histology over time were evaluated according to COJ status. Routine follow-up biopsies were initiated in 2005 and performed 1, 5, and 10 years after PE or when clinically indicated. Follow-up biopsies were taken percutaneously with ultrasound guidance under general anesthesia for endoscopic variceal surveillance. 29 For patients who underwent LT, followup liver histology was mainly based on the explant.
In addition to conventional stains, immunostaining for cytokeratin 7 (CK7) was performed using a rabbit antihuman monoclonal antibody and ultra View Universal DAB Detection Kit (Ventana). Two experienced pediatric Predictors of COJ, bilirubin levels at 3 months after PE, follow-up Metavir score, and fibrosis progression rate were evaluated with regression analyses. For COJ, odds ratios (OR) with 95% CIs were generated by binary logistic regression, and linear regression was used for continuous variables. Predictors showing significant associations with outcomes variables in simple regression were included in multiple regression analyses.
Cumulative native liver and overall survival rates were analyzed with Kaplan-Meier curves. Univariate predictors of survival were evaluated with the log-rank test. Multivariate survival models were performed by generating hazard ratios with 95% CIs with Cox proportional hazards regression model, adjusted for statistically significant variables from univariate models and for age at PE 3, 6, 7 for native liver survival. The level of significance was set at p < 0.05 and all analyses were performed with SPSS, version 24 (IBM Corp).
RESULTS

Baseline characteristics
Altogether 63 patients were identified. Two patients were excluded; 1 died of heart defect before operation and the other with multiple severe anomalies died few weeks after PE; no COJ status for him could be defined. The remaining 61 patients were divided into cohorts A (n ¼ 25 patients [41%]) and B (n ¼ 36 [59%]), depending on whether they were treated before (cohort A) or after (cohort B) the decree on national centralization came into force in 2005. 4 Altogether, 59 patients underwent PE and 1 patient from both cohorts underwent primary LT due to delayed diagnosis and liver failure.
Based on annual birth rates in Finland, 31 the incidence of BA was 1:18,600. Median annual caseload was 1 (IQR 1 to 2) before and 3.5 (IQR 2 to 4.3) after centralization. Cohort B patients underwent PE at younger age, had lower birth weight, and tended to be born earlier and have lower preoperative bilirubin compared with cohort A (Table 1) . Median age at PE was 64 (IQR 39 to 85) days.
Liver biopsies at time of PE were available for half (12 of 24) of cohort A and 97% (34 of 35) of cohort B patients. At PE, histologic features consisted of moderate to severe fibrosis, portal inflammation, ductal reaction, and cholestasis (Table 1) . Ductal reaction and associated periportal HCM correlated with age at operation (r ¼ 0.679; p < 0.001 and r ¼ 0.463; p ¼ 0.002, respectively) and degree of fibrosis (r ¼ 0.539; p < 0.001 and r ¼ 0.454; p ¼ 0.002, respectively). Portal inflammation showed no association with baseline characteristics.
Clearance of jaundice
The proportion of patients clearing their jaundice almost doubled after centralization; 28 of 35 (80%) vs 10 of 24 (42%) (p ¼ 0.005). In total 26% (10 of 38) achieved COJ later than 3 months after operation, and COJ rate at 3 months was 65% in cohort B vs 32% in cohort A (p ¼ 0.028). Median time to COJ showed no difference between cohorts A and B (3. 
In logistic regression, operation after centralization (OR 5.60; 95% CI 1.76 to 17.9; p ¼ 0.004), highgrade portal inflammation (OR 3.66; 95% CI 1.35 to 9.97; p ¼ 0.011), and young age at operation (OR 0.98; 95% CI 0.97 to 1.00; p ¼ 0.025) predicted COJ. In multiple regression, only the effect of portal inflammation remained significant (OR 3.82; 95% CI 1.23 to 11.9; p ¼ 0.020).
Variables associated with bilirubin levels at 3 months in linear regression were operation before centralization (b ¼ 165; 95% CI 77.6 to 252; p < 0.001), age at PE Native liver survival Cumulative native liver survival for cohorts A and B were 37.5% (AESE 9.6%) and 77.6% (AE7.5) at 2 years; 37.5% (AE9.9) and 70.2% (AE8.4) at 5 years; and 33.3% (AE9.6) and 65.2% (AE9.2) at 10 years, respectively (Fig. 1) . Clearance of jaundice, bilirubin levels at 3 and 6 months postoperatively, portal inflammation grade at PE, and centralization were significant predictors of native liver survival (Fig. 1, Table 2 ). Among cohort B patients, BASM and higher periportal HCM at PE predicted shorter native liver survival, and higher ductal reaction at PE tended to predict shorter native liver survival (Table 2 ).
Bilirubin at 3 months after operation was a better predictor compared with bilirubin at 6 months and was therefore chosen for the multivariate analysis. The hazard of death or transplantation was higher if bilirubin was !20 mmol/L at 3 months after operation (hazard ratio 11.0; 95% CI 2.38 to 50.4; p ¼ 0.002), and the effects of centralization, age, or portal inflammation remained insignificant.
Liver transplantation During follow-up, 22 patients (11 from both cohorts, 44% and 31%, respectively) underwent LT at age 1.15 (IQR 0.77 to 2.46) years. One patient from both cohorts underwent primary LT and 20 patients underwent LT after PE. Of them, the majority (n ¼ 15) received transplants because of liver failure after an unsuccessful PE, and indications for LT after initial COJ were liver failure (n ¼ 1), recurrent variceal bleeding (n ¼ 1), recurrent cholangitis (n ¼ 1), hepatopulmonary syndrome (n ¼ 1), or refractory ascites (n ¼ 1). Two patients with BASM died after LT (2 of 5) compared with 17 transplanted patients without BASM surviving until the end of the follow-up (log-rank test; p ¼ 0.006). Centralization, COJ, or baseline characteristics were unrelated with post-LT survival, which was 91% at 2, 5, and 10 years (Fig. 2) . One patient required a retransplantation. Table 3 ). Reasons for death were complications of advanced liver disease (n ¼ 7), intestinal perforation (n ¼ 1), volvulus (n ¼ 1), and heart failure (n ¼ 1). Three patients died on LT waiting list and only 1 of the deceased patients had cleared his jaundice after PE. Univariate analyses suggested survival was better among patients whose bilirubin decreased <20 mmol/L within 3 months of operation (p ¼ 0.001) and who were operated on after centralization (p ¼ 0.007) ( Table 3) . Neither predictor remained significant in multivariate analysis. Fibrosis and periportal HCM increased and ductal reaction persisted in all patients after PE, and cholestasis and portal inflammation decreased only after successful PE and remained unchanged if no COJ was achieved (Fig. 3, Table 4 ). Follow-up fibrosis scores correlated with follow-up ductal reaction (r ¼ 0.494; p ¼ 0.003) and were closely related with periportal HCM, portal inflammation, and their increase during follow-up (Fig. 4) . In simple regression, follow-up fibrosis score was associated with biopsy timing after PE (b ¼ À0.09; 95% CI À0.18 to À0.003; p ¼ 0. The p values from the log-rank test are reported. Results presented separately for cohort B and for the whole sample. *Bilirubin data at 6 months missing for patients who received liver transplant (n ¼ 2) or died (n ¼ 4) before 6 months of PE or in whom bilirubin was not measured at 6 months (n ¼ 1). Results are presented separately for cohort B and for the whole sample. p Values from the log-rank test are reported. Bilirubin levels analyzed only for patients undergoing PE and not primary transplantation (n ¼ 59). *Bilirubin data at 6 months missing for patients who received liver transplantation (n ¼ 2) or died (n ¼ 4) before 6 months of PE or in whom bilirubin was not measured at 6 months (n ¼ 1).
DISCUSSION
This study demonstrates that national centralization of BA management and standardization of care can considerably improve outcomes, even exceeding those reported previously. 3, 7, 32, 33 Although the incidence of BA in Finland is equivalent to other European countries, 6, 21 the annual caseload inevitably remains lower, as Finland's population approximates 5.5 million. After centralization of management, COJ rate increased from 42% to 80%, showing that excellent PE outcomes can be achieved, even with relatively low caseloads, if the treatment process is rationally planned. Reflecting COJ rates, both native liver and overall survival estimates improved significantly. In addition, this study provides novel evidence on BA liver histopathology and its relation to the clinical outcomes. High-grade portal inflammation at PE is associated with improved COJ rates and, consequently, with slower progression of fibrosis and longer native liver survival. Periportal HCM was the only predictor of followup fibrosis in multiple regression, and the extent of (2) 0.282 Results are presented separately for patients who cleared or did not clear their jaundice after PE (bilirubin <20 vs !20 mmol/L). Data are shown for 33 patients with liver histology available both at baseline and at follow-up. Wilcoxon signed-rank test p values for the difference between histology scores at operation and at follow-up are reported. *Mann-Whitney U test p value < 0.05 for the differences observed in histologic scores between COJ and no-COJ subgroups. Mann-Whitney U test p value < 0.01 for the differences observed in histologic scores between COJ and no-COJ subgroups. Mann-Whitney U test p value < 0.001 for the differences observed in histologic scores between COJ and no-COJ subgroups. COJ, clearance of jaundice; PE, portoenterostomy.
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Hukkinen et al Predictors of Biliary Atresia Outcomesboth HCM and ductal reaction paralleled closely the degree of fibrosis at PE and its progression during follow-up. These findings suggest progression of liver damage is partly regulated by inflammation and ductal reaction. After failed PE, BA patients die of liver failure within 2 years unless LT is performed. 8 The PE success rates typically vary between 40% and 60%, 3, 6, 7, 32 with best outcomes reported so far from the UK, where BA treatment has been centralized in 3 hospitals, 21 and from Japan, where BA incidence is remarkably higher compared with Europe. 5 In this study, COJ and 5-year native liver survival rates almost doubled after centralization. Although age at operation decreased simultaneously, regression models suggested centralization was the most important factor predicting postoperative bilirubin levels. In French and Canadian national cohorts, hospitals with the lowest and highest caseloads achieved similar outcomes. 6, 33, 34 Our post-centralization results also suggest that instead of absolute caseload numbers, BA outcomes are influenced by the quality of each treatment aspect, including early diagnosis and appropriate surgical technique, as well as standardized postoperative management and careful follow-up. [25] [26] [27] Postoperative steroids can improve COJ in patients who undergo an early PE, 19, 25 suggesting children managed after centralization at median age of 54 days might have particularly benefited from adjuvant therapy. A combination of steroids, ursodeoxycholic acid, 27 and antibiotics 3, 26 has been previously demonstrated to improve COJ and native liver survival. 35, 36 Unfortunately, because the use and dosage of postoperative medications was variable before centralization, their effect could not be controlled for in statistical analyses.
Bilirubin level at 3 months after operation reflects the success of PE and has outperformed the prognostic value of other factors on native liver survival in several large cohorts.
14,37-39 Also, in our patients, bilirubin at 3 months was the best predictor of native liver and overall survival, and centralization strongly influenced the postoperative reduction of bilirubin. Patients with BASM had higher post-LT mortality and shorter native liver survival in cohort B than others. In addition to BASM, 24, 32, 33 anatomic subtype of BA 6, 13, 14 and age at PE 3, 6, 7, 13 can influence native liver survival. As splenic malformations and BA subtypes 1 to 2 each occur in about 10% of patients, 24, 38 their predictive value is evidently limited. Although increased age at operation relates with shorter transplant-free survival, whether it limits achievement of COJ remains unclear, 3, 7, 14, 38 and no threshold age beyond which PE would be futile has been set. 10 Although we found bilirubin at 3 months as the best predictor of LT need, as much as 26% cleared their jaundice later. Frequent monitoring of clinical status and laboratory values are needed to distinguish between such patients and those who will require LT during infancy. Although previous abdominal operation can increase the risk of complications after LT, mortality after primary transplantation in BA is higher compared with LT performed after PE. 6, 12, 13 In addition, better LT outcomes are achieved in older children compared with infants, 11, 40 which supports the benefit of primary PE unless patients present with liver failure. As malnutrition and stage of liver disease also influence LT outcomes, 39, 40 management of BA in centers with experienced multidisciplinary teams and a transplantation program likely improves patient survival by ensuring appropriate management, as well as timely listing for LT when needed. 10 Centralization of BA treatment in a hospital with such services might, in part, explain the improved outcomes observed in our series. Viral, autoimmune, or toxic triggers are thought to give rise to an inflammatory reaction launching destruction of bile ducts in BA. 1, 8, 41 Different degrees of portal inflammation were present at diagnosis in virtually all of our patients, supporting a proinflammatory cause. Interestingly, higher inflammation scores strongly predicted COJ, longer native liver survival, and slower fibrosis progression. Portal inflammation reduced only after successful PE, which might have been facilitated by postoperative adjuvant therapy use after centralization. 19 At PE, most BA patients present with some degree of liver inflammation, 16, 41 higher levels of which have been reported in cytomegalovirus-associated BA. 42 Besides differential viral cause, a predominantly inflammatory liver histopathology could reflect an earlier and more modifiable stage of BA before irreversible progression to a predominantly fibrotic stage, as suggested by gene expression profiling analyses. 41 We found portal inflammation scores unrelated with age at PE or clinical patient characteristics. Although our sample is limited by its relatively small size and some missing biopsies among cohort A patients, the strong inverse association between inflammation and improved outcomes appears to be a true biologic phenomenon.
The main determinant of the course of BA and need for LT is the progression fibrosis, which pathogenesis is incompletely understood. 22, 43, 44 In BA and other cholangiopathies, a characteristic histologic feature evolving adjacent to fibrosis is ductal reaction, which refers to hepatocytes and/or progenitor cells transdifferentiating into CK7-positive cell lineages, toward either intermediate hepatocytes or epithelial cells forming immature biliary ductules. 17, 43, 45 Although mechanisms behind ductal reaction-driven fibrogenesis remain unclear, worsening fibrosis correlates closely with increasing ductal reaction in several acquired liver diseases. 45, 46 In BA, degree of biliary proliferation predicts native liver survival and reflects the degree of fibrosis at time of PE. 15 , 16 Our results demonstrate that the extent of ductal reaction and associated periportal HCM parallel closely the degree of fibrosis not only at PE but also during the course of BA, suggesting such histopathologic features can promote progressive fibrosis, even when inflammation resolves after successful PE. Notably, in multiple regression, periportal HCM was the only predictor of follow-up fibrosis. In BA animal models, fibrogenic growth factor signaling from ductal reaction seems to activate other cell types to produce extracellular matrix. 47, 48 Further characterization of such interplay 47, 49, 50 is crucial to understanding how to prevent progressive liver injury.
CONCLUSIONS
Based on more than a decade of follow-up after national centralization of BA management, outcomes measured as COJ, native liver survival, and overall survival improved significantly. Resolution of cholestasis and reduction of high-grade portal inflammation after PE is associated with slower fibrosis progression and improved native liver survival. Despite COJ, liver fibrosis progressed in parallel with CK7 immunostaining of proliferating bile ductules and periportal hepatocytes during follow-up, suggesting expanding biliary fibrosis in BA is closely coupled with ductal reaction and associated HCM. To what extent fibrogenesis and ductal reaction are affected by the initial inflammatory reaction remains to be elucidated. While waiting for effective antifibrotic therapies, standardized multidisciplinary treatment protocols, as well as centralization of BA management, can postpone the need for LT and extend patient survival.
